Xynomic Pharmaceuticals Holdings, Inc.
http://xynomicpharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Xynomic Pharmaceuticals Holdings, Inc.
Xynomic Buys Rights to Boehringer's Phase II Ready mTORC1/2 Inhibitor
US-China biopharma is paying up to $800m to Boehringer Ingelheim in connection with in-licensing BI 860585, its second asset purchase from the German big pharma.
Start-Up Quarterly Statistics: 2017 Fundraising Ends Better Than It Began
But Q4 was the third sequential quarter with a decrease in financing totals. A review of biopharma start-up dealmaking and financing activity from October through December 2017, based on data from Strategic Transactions.
Deals Shaping the Medical Industry, January 2018
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2017.
Deal Watch: Boehringer's Busy End Of Year Includes Deals With Roche, Autifony
The German pharma options potassium channel modulator technology from Autifony and partners with Roche on immunological approaches to irritable bowel syndrome. Roche unveils discovery pacts with Confo and DiCE.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Bison Capital Acquisition Corp.
- Xynomic Pharmaceuticals, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice